Meta-Analysis
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Meta-Anal. Nov 26, 2014; 2(4): 212-220
Published online Nov 26, 2014. doi: 10.13105/wjma.v2.i4.212
Using fluorodeoxy-D-glucose-positron emission tomography to monitor neoadjuvant chemotherapy response in sarcoma: A meta-analysis
Yu-Ting Wang, Hong Pu, Long-Lin Yin, Jia-Yuan Chen
Yu-Ting Wang, Hong Pu, Long-Lin Yin, Jia-Yuan Chen, Department of Radiology, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, Chengdu 610072, Sichuan Province, China
Author contributions: Wang YT and Chen JY designed the research; Wang YT, Pu H and Yin LL performed the research; Wang YT and Pu H analyzed the data; Wang YT wrote the manuscript.
Supported by Scientific Research Subject of Health Department of Sichuan, China, No. 070045
Correspondence to: Yu-Ting Wang, MD, Department of Radiology, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, No. 32, Section 2, 1st Ring Road (West), Chengdu 610072, Sichuan Province, China. wangyuting_330@163.com
Telephone: +86-28-87394280
Received: May 13, 2014
Revised: August 11, 2014
Accepted: September 4, 2014
Published online: November 26, 2014
Processing time: 202 Days and 12.6 Hours
Core Tip

Core tip: Histopathological response to neoadjuvant chemotherapy is a significant prognostic factor and could guild the following treatment for patients with sarcoma. Novel molecular imaging such as 18-fluorodeoxy-D-glucose-positron emission tomography (PET) could offer non-invasive and accurate assessment of such response in sarcoma based on our relatively large-sample statistical analysis for this relatively rare tumor. More information that clinical physicians concerned with was generated, such as recommended subgroup of patients, potential candidates for quantitative criteria of response and possible causes of false positives of PET.